Qiagen (NYSE:QGEN) Shares Scheduled to Reverse Split on Thursday, January 8th

Qiagen N.V. (NYSE:QGEN)’s stock is going to reverse split before the market opens on Thursday, January 8th. The 19-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, January 7th.

Qiagen Stock Performance

Shares of QGEN stock opened at $45.30 on Friday. Qiagen has a 12-month low of $37.63 and a 12-month high of $51.88. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.60 and a quick ratio of 2.30. The firm has a market capitalization of $10.07 billion, a price-to-earnings ratio of 24.62, a price-to-earnings-growth ratio of 2.32 and a beta of 0.68. The business has a 50 day simple moving average of $46.10 and a 200 day simple moving average of $47.10.

Qiagen (NYSE:QGEN) last announced its earnings results on Thursday, November 6th. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.03. The firm had revenue of $532.58 million for the quarter, compared to the consensus estimate of $525.68 million. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.57 EPS. On average, equities research analysts anticipate that Qiagen will post 2.26 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Barclays restated an “overweight” rating and issued a $55.00 price objective (up previously from $53.00) on shares of Qiagen in a report on Monday, December 15th. Wall Street Zen upgraded shares of Qiagen from a “hold” rating to a “buy” rating in a research report on Sunday, December 21st. Citigroup downgraded shares of Qiagen from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $55.00 to $50.00 in a report on Thursday, December 11th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a report on Monday. Two research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, Qiagen has a consensus rating of “Hold” and a consensus target price of $49.61.

Institutional Investors Weigh In On Qiagen

Several large investors have recently made changes to their positions in QGEN. Walleye Trading LLC raised its position in Qiagen by 14.6% during the first quarter. Walleye Trading LLC now owns 7,367 shares of the company’s stock valued at $296,000 after acquiring an additional 936 shares in the last quarter. State of Wyoming increased its stake in shares of Qiagen by 358.2% during the 1st quarter. State of Wyoming now owns 12,775 shares of the company’s stock worth $513,000 after purchasing an additional 9,987 shares during the last quarter. Vident Advisory LLC bought a new position in shares of Qiagen during the 1st quarter valued at $604,000. Graham Capital Management L.P. lifted its stake in shares of Qiagen by 92.7% in the 1st quarter. Graham Capital Management L.P. now owns 68,114 shares of the company’s stock valued at $2,735,000 after purchasing an additional 32,774 shares during the last quarter. Finally, AQR Capital Management LLC boosted its holdings in Qiagen by 69.4% in the first quarter. AQR Capital Management LLC now owns 178,425 shares of the company’s stock worth $7,164,000 after purchasing an additional 73,122 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.